Boehringer Ingelheim Vetmedica Gmbh

Intervet Inc.

Other

Boehringer Ingelheim Animal Health USA Inc.

Vicky Fachinger

Knut Elbers

Marion Kixmoeller

Axel Lischewski

Francois-Xavier Orveillon

Isabelle Freiin Von Richthofen

Melanie Sno

Michael Dennis Piontkowski

Maarten Hendrik Witvliet

Isabelle Von Richthofen

Francois Xavier Orveillon

Antonius Arnoldus Christiaan Jacobs

Chen Shu-hui Tan

Pieter Van Gelder

Isabelle Frein Von Richthofen

Michael Piontkowski

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

Vaccine for intradermal application against PCV2 and PRRS virus infection

The present invention pertains to a vaccine for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus, the vaccine comprising in combination non-replicating immunogen of porcine circovirus type 2 and live attenuated PRRS virus, wherein the vaccine additionally comprises albumin.

Combination vaccine against PCV2 and PRRS virus infection comprising albumin

The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.

Treatment of pigs with PCV2 antigen

The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.

Vaccine against Lawsonia intracellularis and porcine circovirus 2

The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.

Vaccine against porcine circo virus type 2

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.

Treatment of PRDC in pigs

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.

Prevention and treatment of sub-clinical PCVD

The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and() antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) andassociated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by, or a method for reduction of clinical symptoms caused by or associated with a PCV2 andinfection, comprising the step of administering an effective amount of PCV2 antigen andantigen to an animal in need of such treatment.

[object Object]

Prophylaxis and treatment of PRDC

The present invention relates to methods for the release of baculovirus-expressed Virus-like Particles (VLP's) of non-enveloped viruses from insect cells.

Methods for the release of Virus-like Particles

The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen.

Growing community of inventors

Bad Soden, Germany

Vicky Fachinger